Posters

Outcome of customised corneal collagen cross-linking for keratoconus patients in Oman: 3–12 months' results

Poster Details

First Author: R.Al Saidi OMAN

Co Author(s):    M. Abdo   A. Bandara   S. Alharthi   J. Babu           

Abstract Details

Purpose:

To report 3-12 months outcome of customized corneal collagen crosslinking for keratoconus patients in Oman.

Setting:

This prospective study is planned to carry out at the ophthalmology center, MOD-Hospital, Muscat, Oman  with 12 months follow up period starting from 2nd September 2018

Methods:

Diagnosed Keratoconus patients in the age group of 12-30 with documented progression of ³ 1 diopter over 6 months period and thinnest pachymetry > 400 mm was included in the study. Epithelium was removed and corneal collagen crosslinking was carried out with application of  Riboflavin followed by UVA light. The treatment area and energy level  were customized according to the topographic findings. Clinical evaluation included uncorrected distance visual acuity (UCVA), corrected distance visual acuity(BCVA), corneal topography, pachymetry, and K-reading. Assessment was  scheduled as pre-op and post-op from 1 month, 3 months, 6 months, 9 months and 12 months

Results:

Total 54 eyes were treated from 2nd September to 17th October 2018. At 3-months post-procedure, 7 eyes (13%) showed deterioration (0.2- 0.4 logMAR) of UCVA while 26 eyes (48.1%) remained same and 21 eyes ( 38.9 %) improved (0.1 – 1.7 logMAR). BCVA showed deterioration (0.1- 0.3 logMAR) in 8 eyes (14.8%) while 28 eyes(51.9 %) didn’t show any change and 18 eyes (33.3%) showed improvement (0.1- 0.5 logMAR). Considering the corneal steepness; 16 eyes (29.6 %) showed further steepening ( Kmax 0.1 -1.9) while one eye (1.9%) remained same and 37 eyes (68.5 %) showed flattening (Kmax 0.2- 5.0).

Conclusions:

The epithelium-off customized corneal collagen crosslinking was effective in stabilizing the progression of keratoconus in the majority of patients in this study group. Early results of this novel application of collagen cross-linking are encouraging but longer-term data in larger studies are required

Financial Disclosure:

None